Biohaven Ltd. (BHVN)
(Delayed Data from NYSE)
$41.19 USD
+0.50 (1.23%)
Updated May 6, 2024 04:00 PM ET
After-Market: $41.22 +0.03 (0.07%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth A Momentum C VGM
Brokerage Reports
Biohaven Ltd. [BHVN]
Reports for Purchase
Showing records 1 - 20 ( 268 total )
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
The Sequel Moves Towards the Main Scene; PT Up to $63 as Key Programs Advance
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Biohaven 2.0 Is a Sequel Worth Buying; Initiating Coverage at Buy With $50 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BHVN 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 9/23/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 9/23/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 9/16/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 8/19/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 8/5/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
With PFE Acquisition On Track, Downgrading To Neutral Rating
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 7/29/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 7/1/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 6/24/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 6/17/22
Provider: Wedbush Securities Inc.
Analyst: CHICO L